Medindia

X

Optimer Pharmaceuticals Announces Presentations of Additional Data From the Fidaxomicin North American Phase 3 Trial at Upcoming IDSA Annual Meeting

Tuesday, October 20, 2009 General News J E 4
Advertisement


SAN DIEGO, Oct. 19 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional data related to fidaxomicin, the Company's lead developmental product candidate for the treatment of Clostridium difficile infection, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at The Philadelphia Convention Center in Philadelphia, Pennsylvania October 29 through November 1, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)



About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

"Age, Serum Albumin, and Leukocytosis/Fever Predict Clinical Outcomes of Clostridium difficile Infection Treated with Fidaxomicin and Vancomycin" Poster Presentation: Mark A. Miller, M.D. Friday, October 30, 2009 12:30pm-2:00pm Eastern Time Poster session: 053, Hospital-acquired and Transplant Infections Presentation #: 420 "Faster Time to Resolution of Diarrhea with Fidaxomicin vs. Vancomycin in Patients with Clostridium difficile Infection" Poster Presentation: Mark A. Miller, M.D. Friday, October 30, 2009 12:30pm-2:00pm Eastern Time Poster session: 053, Hospital-acquired and Transplant Infections Presentation #: 422 "Effect of Concomitant Antibiotics on Treatment of Clostridium difficile Infection with Fidaxomicin or Vancomycin" Poster Presentation: Kathleen M. Mullane, D.O. Saturday, October 31, 2009 12:30pm-2:00pm Eastern Time Poster session: 110, Late Breaker Posters Presentation #: LB-14

SOURCE Optimer Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Presentation of Adult Stem Cell Study Highlights P...
S
Indiana Health Information Exchange's Innovative Q...